http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022175973-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c4e52fb9d1643ab7c5af03a0db80466 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2022-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c6119676e31bb3d8255c98162ecfb07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0e852502a533a6a5c79db6435a87cc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79166bea255b96d701a671d4a354a6d0 |
| publicationDate | 2022-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022175973-A1 |
| titleOfInvention | An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof |
| abstract | The present invention provides a long term, liquid injectable pharmaceutically acceptable composition for sustained release of nalbuphine or a nalbuphine ester prodrug, or the pharmaceutically acceptable salts of nalbuphine, comprising one or more biocompatible non-aqueous solvents with one or more stabilizers, wherein the injection is administered subcutaneously or intramuscularly. The invention also provides method for treating pain with the duration of action of the injectable pharmaceutical composition of about 7 days to 15 days and/or the release period of the pharmaceutical formulation is about 15 days from dosing in patients by administering an effective amount of the liquid injectable pharmaceutical composition of nalbuphine or a nalbuphine ester prodrug, or the pharmaceutically acceptable salts of nalbuphine. The pain may be moderate to severe, acute pain, chronic pain, nociceptive pain, neuropathic pain, visceral pain, idiopathic pain, post-operative pain and pain in terminal cancer. |
| priorityDate | 2021-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.